BRPI0817130A2 - Composto, sal ou solvato farmaceuticamente aceitáveis ou uma mistura dos mesmos; composição farmacêutica, composição farmacêutica embalada; método para tratar um paciente, aumentar a sensibilidade das células cancerígenas à quimioterapia, reduzir erros de medição e melhorar a conformidade terapêutica, inibir a hidrólise atp e a atividade das células b e determinar a presença de btk - Google Patents
Composto, sal ou solvato farmaceuticamente aceitáveis ou uma mistura dos mesmos; composição farmacêutica, composição farmacêutica embalada; método para tratar um paciente, aumentar a sensibilidade das células cancerígenas à quimioterapia, reduzir erros de medição e melhorar a conformidade terapêutica, inibir a hidrólise atp e a atividade das células b e determinar a presença de btkInfo
- Publication number
- BRPI0817130A2 BRPI0817130A2 BRPI0817130A BRPI0817130A2 BR PI0817130 A2 BRPI0817130 A2 BR PI0817130A2 BR PI0817130 A BRPI0817130 A BR PI0817130A BR PI0817130 A2 BRPI0817130 A2 BR PI0817130A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- btk
- solvate
- chemotherapy
- patient
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002512 chemotherapy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000007062 hydrolysis Effects 0.000 title 1
- 238000006460 hydrolysis reaction Methods 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000005259 measurement Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 230000035945 sensitivity Effects 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97399507P | 2007-09-20 | 2007-09-20 | |
| US5077708P | 2008-05-06 | 2008-05-06 | |
| PCT/US2008/077054 WO2009039397A2 (en) | 2007-09-20 | 2008-09-19 | Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0817130A2 true BRPI0817130A2 (pt) | 2015-03-31 |
Family
ID=40377565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0817130 BRPI0817130A2 (pt) | 2007-09-20 | 2008-09-19 | Composto, sal ou solvato farmaceuticamente aceitáveis ou uma mistura dos mesmos; composição farmacêutica, composição farmacêutica embalada; método para tratar um paciente, aumentar a sensibilidade das células cancerígenas à quimioterapia, reduzir erros de medição e melhorar a conformidade terapêutica, inibir a hidrólise atp e a atividade das células b e determinar a presença de btk |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7884108B2 (enExample) |
| EP (1) | EP2188267B1 (enExample) |
| JP (1) | JP5485894B2 (enExample) |
| KR (1) | KR20100072032A (enExample) |
| CN (1) | CN101861307B (enExample) |
| AR (1) | AR068503A1 (enExample) |
| AU (1) | AU2008302099B2 (enExample) |
| BR (1) | BRPI0817130A2 (enExample) |
| CA (1) | CA2700443A1 (enExample) |
| CL (1) | CL2008002793A1 (enExample) |
| PE (1) | PE20091201A1 (enExample) |
| RU (1) | RU2470923C2 (enExample) |
| TW (1) | TWI423966B (enExample) |
| WO (1) | WO2009039397A2 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20080839A1 (es) * | 2006-09-11 | 2008-08-23 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
| US7838523B2 (en) * | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| ES2554615T3 (es) * | 2008-05-06 | 2015-12-22 | Gilead Connecticut, Inc. | Amidas sustituidas, método de preparación y utilización como inhibidores de Btk |
| CN103408533B (zh) | 2008-06-24 | 2015-08-26 | 霍夫曼-拉罗奇有限公司 | 新型取代的吡啶-2-酮和哒嗪-3-酮 |
| CA2728683C (en) | 2008-07-02 | 2017-05-02 | F.Hoffmann-La Roche Ag | Novel phenylpyrazinones as kinase inhibitors |
| BR112012028530A2 (pt) * | 2010-05-07 | 2017-12-19 | Genentech Inc | composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno |
| ES2561277T3 (es) | 2010-09-01 | 2016-02-25 | Gilead Connecticut, Inc. | Piridinonas/pirazinonas, procedimiento de preparación y procedimiento de utilización de las mismas |
| UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| MX2014005285A (es) | 2011-11-03 | 2014-05-30 | Hoffmann La Roche | Compuestos biciclicos de piperazina. |
| RU2622391C2 (ru) | 2011-11-03 | 2017-06-15 | Ф. Хоффманн-Ля Рош Аг | Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона |
| MX2014005289A (es) | 2011-11-03 | 2014-05-30 | Hoffmann La Roche | Compuestos de piperazina alquilados. |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| EP3366685A1 (en) | 2012-01-09 | 2018-08-29 | X-Chem, Inc. | Tryptoline derivatives having kinase inhibitory activity and uses thereof |
| WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2014108820A1 (en) * | 2013-01-08 | 2014-07-17 | Aurigene Discovery Technologies Limited | Substituted 2-pyrazinone derivatives as kinase inhibitors |
| WO2014125410A1 (en) * | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | N-substituted heterocyclic derivatives as kinase inhibitors |
| PH12020550201A1 (en) * | 2013-03-15 | 2024-01-15 | Deciphera Pharmaceuticals Llc | N-acyl-n-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
| BR112015025260B1 (pt) | 2013-04-25 | 2021-11-03 | Beigene, Ltd | Compostos heterocíclicos fundidos como inibidores da proteína quinase, sua composição, combinação e uso |
| BR112015031835B1 (pt) * | 2013-06-19 | 2022-12-13 | Som Innovation Biotech, S.L | Usos de agentes terapêuticos, de uma combinação dos referidos agentes com um agente terapêutico adicional, e de uma composição farmacêutica para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético |
| KR101815360B1 (ko) | 2013-07-03 | 2018-01-04 | 에프. 호프만-라 로슈 아게 | 헤테로아릴 피리돈 및 아자-피리돈 아마이드 화합물 |
| WO2015017460A1 (en) | 2013-07-30 | 2015-02-05 | Gilead Connecticut, Inc. | Polymorph of syk inhibitors |
| US9918939B2 (en) | 2013-07-30 | 2018-03-20 | Gilead Connecticut, Inc. | Formulation of Syk inhibitors |
| ES2927567T3 (es) | 2013-09-13 | 2022-11-08 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| SMT202000273T1 (it) * | 2013-10-18 | 2020-07-08 | Celgene Quanticel Research Inc | Inibitori di bromodomini |
| EP2876124B1 (de) | 2013-11-20 | 2019-01-09 | Uhde Inventa-Fischer GmbH | Verfahren sowie vorrichtung zur herstellung einer kristallisierbaren polymilchsäuremischung sowie polymilchsäuremischung |
| CN105793251B (zh) | 2013-12-05 | 2018-10-12 | 豪夫迈·罗氏有限公司 | 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物 |
| CA2932609A1 (en) | 2013-12-05 | 2015-06-11 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
| WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
| WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
| SI3160956T1 (sl) | 2014-06-27 | 2020-11-30 | Celgene Quanticel Research, Inc. | Inhibitorji lizin-specifične demetilaze-1 |
| CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| PL3164380T3 (pl) * | 2014-07-03 | 2022-04-04 | Celgene Quanticel Research, Inc. | Inhibitory lizyno-specyficznej demetylazy-1 |
| WO2016139361A1 (en) * | 2015-03-05 | 2016-09-09 | Boehringer Ingelheim International Gmbh | New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9 |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| DK3377488T3 (da) | 2015-11-19 | 2022-10-03 | Incyte Corp | Heterocykliske forbindelser som immunomodulatorer |
| SG10202005790VA (en) | 2015-12-22 | 2020-07-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| CN107033069B (zh) * | 2016-02-04 | 2022-03-04 | 中国科学院合肥物质科学研究院 | 一种新型布鲁顿酪氨酸激酶不可逆抑制剂 |
| ES3022188T3 (en) | 2016-02-29 | 2025-05-28 | Hoffmann La Roche | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| HRP20200728T1 (hr) | 2016-04-15 | 2020-07-24 | Abbvie Inc. | Inhibitori bromodomene |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA45116A (fr) | 2016-05-26 | 2021-06-02 | Incyte Corp | Composés hétérocycliques comme immunomodulateurs |
| BR112018076534A2 (pt) * | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| SG11201901141WA (en) | 2016-08-16 | 2019-03-28 | Beigene Ltd | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| CA3034326A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| BR112019005337A2 (pt) | 2016-09-19 | 2019-08-27 | Mei Pharma Inc | terapia combinada |
| CA3042297A1 (en) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| EP3558985B1 (en) | 2016-12-22 | 2022-09-07 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| MD3558990T2 (ro) | 2016-12-22 | 2023-02-28 | Incyte Corp | Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1 |
| WO2018124281A1 (ja) * | 2016-12-28 | 2018-07-05 | 富山化学工業株式会社 | 外用組成物 |
| WO2018137681A1 (en) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof |
| EP3602058A1 (en) | 2017-03-24 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Methods of treating autoimmune and inflammatory diseases |
| KR102757960B1 (ko) | 2017-06-26 | 2025-01-22 | 베이진 엘티디 | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 |
| US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
| JP6986624B2 (ja) | 2017-08-25 | 2021-12-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｓｙｋ阻害剤の多形体 |
| KR102613433B1 (ko) | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| CA3085457C (en) | 2018-01-29 | 2023-05-23 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| HRP20230090T1 (hr) | 2018-03-30 | 2023-03-17 | Incyte Corporation | Heterociklički spojevi kao imunomodulatori |
| PT3790877T (pt) | 2018-05-11 | 2023-05-10 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1 |
| MX2021010131A (es) | 2019-02-22 | 2021-11-18 | Kronos Bio Inc | Formas sólidas de pirazinas condensadas a manera de inhibidores de syk. |
| TWI856111B (zh) | 2019-06-10 | 2024-09-21 | 瑞士商百濟神州瑞士有限責任公司 | 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法 |
| AR119624A1 (es) | 2019-08-09 | 2021-12-29 | Incyte Corp | Sales de un inhibidor de pd-1 / pd-l1 |
| MX2022003578A (es) | 2019-09-30 | 2022-05-30 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores. |
| IL292524A (en) | 2019-11-11 | 2022-06-01 | Incyte Corp | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| CN112812113B (zh) * | 2019-11-15 | 2022-09-20 | 杭州和正医药有限公司 | 免疫调节化合物、组合物及其应用 |
| CN114380841B (zh) * | 2020-10-19 | 2025-12-30 | 南京正大天晴制药有限公司 | 作为akt抑制剂的三环喹唑啉或二氢喹唑啉化合物 |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| CR20230230A (es) | 2020-11-06 | 2023-07-27 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| US7405295B2 (en) * | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| AU2006223409B2 (en) * | 2005-03-10 | 2011-07-21 | Gilead Connecticut, Inc. | Certain substituted amides, method of making, and method of use thereof |
| PE20080839A1 (es) * | 2006-09-11 | 2008-08-23 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
| JP2010502751A (ja) | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ，インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
-
2008
- 2008-09-17 CL CL2008002793A patent/CL2008002793A1/es unknown
- 2008-09-19 PE PE2008001640A patent/PE20091201A1/es not_active Application Discontinuation
- 2008-09-19 JP JP2010526003A patent/JP5485894B2/ja active Active
- 2008-09-19 EP EP08832237.5A patent/EP2188267B1/en active Active
- 2008-09-19 WO PCT/US2008/077054 patent/WO2009039397A2/en not_active Ceased
- 2008-09-19 CA CA2700443A patent/CA2700443A1/en not_active Abandoned
- 2008-09-19 TW TW097136216A patent/TWI423966B/zh not_active IP Right Cessation
- 2008-09-19 RU RU2010115574/04A patent/RU2470923C2/ru active
- 2008-09-19 AU AU2008302099A patent/AU2008302099B2/en not_active Ceased
- 2008-09-19 KR KR1020107008468A patent/KR20100072032A/ko not_active Withdrawn
- 2008-09-19 BR BRPI0817130 patent/BRPI0817130A2/pt not_active Application Discontinuation
- 2008-09-19 AR ARP080104094A patent/AR068503A1/es unknown
- 2008-09-19 US US12/234,281 patent/US7884108B2/en active Active
- 2008-09-19 CN CN2008801161200A patent/CN101861307B/zh active Active
-
2010
- 2010-11-04 US US12/939,518 patent/US8247550B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20090082330A1 (en) | 2009-03-26 |
| AU2008302099A1 (en) | 2009-03-26 |
| TW200914446A (en) | 2009-04-01 |
| JP2010540452A (ja) | 2010-12-24 |
| US20110059944A1 (en) | 2011-03-10 |
| WO2009039397A2 (en) | 2009-03-26 |
| US7884108B2 (en) | 2011-02-08 |
| EP2188267A2 (en) | 2010-05-26 |
| CL2008002793A1 (es) | 2009-09-04 |
| CN101861307A (zh) | 2010-10-13 |
| KR20100072032A (ko) | 2010-06-29 |
| CA2700443A1 (en) | 2009-03-26 |
| RU2010115574A (ru) | 2011-10-27 |
| CN101861307B (zh) | 2013-05-01 |
| WO2009039397A3 (en) | 2009-05-22 |
| RU2470923C2 (ru) | 2012-12-27 |
| TWI423966B (zh) | 2014-01-21 |
| JP5485894B2 (ja) | 2014-05-07 |
| US8247550B2 (en) | 2012-08-21 |
| EP2188267B1 (en) | 2016-08-03 |
| AR068503A1 (es) | 2009-11-18 |
| PE20091201A1 (es) | 2009-09-13 |
| AU2008302099B2 (en) | 2013-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0817130A2 (pt) | Composto, sal ou solvato farmaceuticamente aceitáveis ou uma mistura dos mesmos; composição farmacêutica, composição farmacêutica embalada; método para tratar um paciente, aumentar a sensibilidade das células cancerígenas à quimioterapia, reduzir erros de medição e melhorar a conformidade terapêutica, inibir a hidrólise atp e a atividade das células b e determinar a presença de btk | |
| Tomaselli et al. | Epigenetic polypharmacology: a new frontier for epi‐drug discovery | |
| Shah et al. | Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead | |
| AR087545A1 (es) | 1h-imidazo[4,5-c]quinolina sustituidos con actividad inhibitoria de bromodominio | |
| PL3599237T3 (pl) | Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta | |
| ATE557015T1 (de) | 3,4-diarylpyrazole als proteinkinaseinhibitoren | |
| EP2506850A4 (en) | METHOD FOR THE ADMINISTRATION OF PIRFENIDON THERAPY | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| BR112014017985A8 (pt) | Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer | |
| US20170172979A1 (en) | Inhibitors of leukotriene-mediated activity for treating side effects of statin therapy | |
| BR112012020270A2 (pt) | sistema e método para administrar medicamentos com base em valores de urina. | |
| US20230158002A1 (en) | Methods and compositions for treatment of myelodysplastic syndromes and/or acute myeloid leukemias | |
| BR112013026397A2 (pt) | Compostos cromenona como inibidores de pi 3-cinase para o tratamento de câncer | |
| Gouda et al. | A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer | |
| Richardson et al. | Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma | |
| Bureta et al. | Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma | |
| BR112014029439A2 (pt) | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos | |
| MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
| KR20160135230A (ko) | 암의 치료를 위한 병용 요법으로서의 에리불린 및 mTOR 억제제의 용도 | |
| Langdon et al. | SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells | |
| BR112013018598A2 (pt) | composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca | |
| JP2021105005A (ja) | 癌治療 | |
| BR112012020060A2 (pt) | composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo na fabricação de um medicamento, composição farmacêutica e método para o tratamento de demência em um sujeito animal incluindo um sujeito mamífero. | |
| Ha et al. | Targeting stress induction of GRP78 by cardiac glycoside oleandrin dually suppresses cancer and COVID-19 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |